Hydroxyurea was administered in a clinical trial to fourteen patients with documented disseminated malignant melanoma. The drug was not found to be useful as the sole agent in this neoplastic disorder in the dosage regimen outlined. The response of three patients receiving radiotherapy to metastatic brain lesions in combination with hydroxyurea was encouraging enough to warrant a further evalua...

For citation purposes: Zhang K, Kim C, Wu X, Loera S, Wang Y, Chu P, Lim D, Shibata S, Yen Y. A phase II study of hydroxyurea combined with gemcitabine in patients with head and neck squamous carcinoma and gene expression profiles correlated to poor response. Head Neck Oncol. 2013 Feb 27;5(3):25. A phase II study of hydroxyurea combined with gemcitabine in patients with head and neck squamous c...

We report serial CNS findings in a girl with sickle cell disease and stroke. Religious considerations precluded transfusion and bone marrow transplantation; therefore, she received single-agent hydroxyurea therapy for almost 6 years. MR angiography showed that vascular patency improved, although diffuse cerebral atrophy slowly worsened. Hydroxyurea can be effective in treating vasculopathy, but...

Concomitant polycythemia vera (PV) and primary cutaneous T-cell lymphomas (CTCL) is very rare. In this report, we describe a patient who developed CTCL after PV, receiving long-term hydroxyurea for PV. The patient referred with large Erythematous patches and plaques on back, flanks and legs. The pathology report showed CTCL. Also, the case had had PV since twenty years ago with phlebotomy as th...